Alliance Global, Amgen Team on Cancer Mutation Testing in Middle East and Africa | GenomeWeb

NEW YORK (GenomeWeb News) – Alliance Global today said that it has signed an agreement with Amgen to provide cancer mutation testing in certain countries in the Middle East and Africa.

The partners have established a program to provide next-generation sequencing-based screening to identify colorectal cancer patients who have mutations in the RAS family of genes. They will utilize Illumina's MiSeqDx platform in screening the patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.